Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1fludarabine 1cobimetinib 1TAK-981 1Ipilimumab 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Combined Modality Therapy 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced or Metastatic Solid Tumors × pembrolizumab × Clear all
NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Recruiting
245 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Recruiting
292 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Completed
161 enrolled 44 charts
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

DynamiCure Biotechnology

Phase 1 Recruiting
320 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡